Sextaphag
Biologicalexperimental
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
2
Phase 4
0
Earliest trial started Jan 1, 2020 (NCT04325685)
Timeline
Indications
Mechanism of action
- BacteriophageImmunity, active
Bacteriophage immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06870409 | Phase 3 | Feb 5, 2025 | university na Patrice Lumumba |
| NCT05182749 | Phase 1/Phase 2 (Phase 2) | Sep 1, 2022 | Intralytix, Inc., University of Maryland |
| NCT05269134 | Phase 2/Phase 3 (Phase 3) | Apr 30, 2022 | Adaptive Phage Therapeutics, Inc. |
| NCT04325685 | N/A | Jan 1, 2020 | Northern State Medical University |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Adaptive Phage Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2022 |
| Intralytix, Inc. | For profit | 1 | 1 | 1 | 2022 |
| Northern State Medical University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| university na Patrice Lumumba | Academic/Hospital | 1 | 1 | 1 | 2025 |
| University of Maryland | Academic/Hospital | 1 | 0 | 1 | 2022 |
5 organizations
Page 1 / 1